TrialBMJ open2020

Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial.

Bruno Vincenzi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.